These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34692681)
1. Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Purcell E; Owen S; Prantzalos E; Radomski A; Carman N; Lo TW; Zeinali M; Subramanian C; Ramnath N; Nagrath S Front Cell Dev Biol; 2021; 9():724389. PubMed ID: 34692681 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor]. Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170 [No Abstract] [Full Text] [Related]
3. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267 [TBL] [Abstract][Full Text] [Related]
4. Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA. Pasini L; Notarangelo M; Vagheggini A; Burgio MA; Crinò L; Chiadini E; Prochowski AI; Delmonte A; Ulivi P; D'Agostino VG Mol Oncol; 2021 Sep; 15(9):2423-2438. PubMed ID: 33942501 [TBL] [Abstract][Full Text] [Related]
5. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482 [TBL] [Abstract][Full Text] [Related]
6. The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer. Suryavanshi M; Mehta A; Panigrahi MK; Jaipuria J; Saifi M; Jain K; Kumar D; Verma H; Sharma SK; Batra U; Dutta K; Talwar V; Doval DC Lung India; 2018; 35(5):384-389. PubMed ID: 30168456 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650 [TBL] [Abstract][Full Text] [Related]
8. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Wang W; Song Z; Zhang Y Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. Li Y; Xu Y; Wu X; He C; Liu Q; Wang F J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130 [TBL] [Abstract][Full Text] [Related]
11. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Xiong L; Cui S; Ding J; Sun Y; Zhang L; Zhao Y; Gu A; Chu T; Wang H; Zhong H; Ye X; Gu Y; Zhang X; Hu M; Jiang L Oncotarget; 2017 Sep; 8(38):63846-63856. PubMed ID: 28969034 [TBL] [Abstract][Full Text] [Related]
13. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085 [TBL] [Abstract][Full Text] [Related]
14. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
15. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593 [TBL] [Abstract][Full Text] [Related]
16. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients. Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441 [TBL] [Abstract][Full Text] [Related]